Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye

Status Withdrawn

Clinical Trial Summary

Clinical Trial Description

The purpose of this study is to explore whether the drug pegylated-interferon-alfa-2b (PEG-IFN)has any effect on a certain type of immune cell (called natural killer cells) in patients with eye melanoma. Because this drug is currently being investigated for use against skin melanoma, we think this drug might have some benefit in eye melanoma as well, and that natural killer cells might be important in how the drug works.

Patients who choose to take part in the study will be randomized to receive either no drug, or PEG-IFN. Four days prior to the patient's surgery to remove the eye, 50cc of blood will be drawn. Patients who are randomized to PEG-IFN will be given the drug once, 4 days prior to surgery. Blood will also be drawn on the day of surgery (50cc), 1 week after surgery (50cc), 1 month (500cc), and 6 months (50cc). ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00621439
Study type	Interventional
Source	Emory University
Contact
Status	Withdrawn
Phase	N/A
Start date	March 2007

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04364230` - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)	Phase 1/Phase 2
Completed	`NCT01200238` - STA-9090(Ganetespib) in Metastatic Ocular Melanoma	Phase 2
Completed	`NCT02858869` - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases	Phase 1
Completed	`NCT01355120` - THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease	Phase 2
Recruiting	`NCT05524935` - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma	Phase 2
Recruiting	`NCT05628883` - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma	Phase 1
Active, not recruiting	`NCT05187884` - Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma	Phase 2
Recruiting	`NCT02909517` - The Role of Inflammation in Ocular Tumours
Terminated	`NCT00346372` - Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
Recruiting	`NCT03172299` - Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma	Phase 3
Not yet recruiting	`NCT06432660` - Eye Plaque Brachytherapy for Ocular Melanoma
Completed	`NCT01893099` - Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma	Phase 1
Completed	`NCT00351728` - Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone	N/A
Active, not recruiting	`NCT03528408` - Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma	Phase 2
Completed	`NCT03052127` - Study in Subjects With Small Primary Choroidal Melanoma	Phase 1/Phase 2
Withdrawn	`NCT01930968` - Definity for Ultrasound of Intraocular Tumors
Recruiting	`NCT00168870` - Study of Metastatic Ocular Melanoma	Phase 2
Completed	`NCT02519322` - Neoadjuvant and Adjuvant Checkpoint Blockade	Phase 2
Recruiting	`NCT06007690` - A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma	Phase 3
Active, not recruiting	`NCT04417530` - Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma	Phase 2